EU Commission grants Lundbeck orphan drug status for asedebart in endogenous Cushing’s syndrome

• European Commission granted orphan drug designation for Lundbeck’s asedebart, an investigational anti-ACTH monoclonal antibody for endogenous Cushing’s syndrome.
• Designation supports development in a rare disorder; a proof-of-concept trial in Cushing’s disease remains ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H. Lundbeck A/S published the original content used to generate this news brief via Cision (Ref. ID: 202608240300BITN____UKPR__EN_20260821-BIT-0696-0) on August 24, 2026, and is solely responsible for the information contained therein.